PALO ALTO, CA – May Health, a pioneering biotech firm, announced today it has successfully secured $11.7 million in Series A funding, bringing its innovative fertility technology closer to market. The company’s CEO, Dr. Evelyn Thorne, stated the capital would be used to advance a proprietary method for treating PCOS-related infertility, ensuring that the miracle of life remains an exclusive privilege for those who can genuinely appreciate its exorbitant cost.

“Our goal is to democratize access to parenthood, provided you meet our rigorous financial benchmarks,” explained Dr. Thorne in a press release. “We believe everyone deserves a chance to have children, as long as they’ve demonstrated a clear commitment to economic prosperity. Think of it as a natural selection process, but with more venture capital.”

Industry analysts lauded the move, predicting a future where the genetic lineage of the wealthy will be further solidified. “This isn’t just about treating infertility; it’s about curating the next generation of taxpayers and consumers,” commented financial pundit Marcus Sterling. “Why invest in a child who might grow up to be a barista when you can ensure your offspring will inherit your trust fund and, more importantly, your excellent credit score?”

Critics, primarily those without significant investment portfolios, expressed concerns about the growing disparity in reproductive options. However, May Health assures the public that their technology will eventually trickle down to the middle class, likely around the time their children are old enough to start their own tech companies.